PDMR/PCA Transaction Notification

RNS Number : 2527R

Shield Therapeutics PLC

04 March 2021

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

PDMR/PCA Transaction Notification

London, UK, 04 March 2021:   Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that Mrs Carmen Hasler, wife of Hans Peter Hasler, Chairman, acquired 200,000 Ordinary Shares in the Company on 03 March 2021 at an average price of 0.37375 pence per share.

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

1.	Details of the person discharging managerial responsibilities / person closely associated
a.	Name	Carmen Hasler
2.	Reason for the notification
a.	Position/status	Wife of Hans Peter Hasler, Non-Executive Chairman
b.	Initial notification /Amendment	Initial
3.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a.	Name	Shield Therapeutics plc
b.	LEI	213800G74QWY15FC3W71
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a.	Description of the Financial instrument, type of instrument Identification code	Ordinary shares of 1.5p each in the capital of the Company ISIN of Ordinary Shares: GB00BYV81293
b.	Nature of the transaction	Acquisition of Ordinary Shares
c.	Price(s) and volume(s)	Price(s) Volume(s) £0.37375 200,000
d.	Aggregated information · Aggregated volume · Price	200,000 £74,750
e.	Date of the transaction	2021-03-03
f.	Place of the transaction	London Stock Exchange, AIM Market

For further information, please contact:

Shield Therapeutics plc	[phone]
Tim Watts (CEO)
Peel Hunt LLP - Nominated Adviser, Joint Broker and Bookrunner			[phone]
James Steel / Dr Christopher Golden
finnCap Ltd - Joint Broker and Bookrunner	[phone]
Geoff Nash / Matthew Radley / Alice Lane
Walbrook PR - Financial PR & IR Adviser		[phone]
Paul McManus / Lianne Cawthorne	or [e-mail]

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol)®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com

 

END

 

 

DSHDKQBDFBKDPNK